Royce & Associates’s Rigel Pharmaceuticals RIGL Stock Holding History

Royce & Associates’s Portfolio RIGL Stock Details RIGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-1,412	Closed	-$37K	–	1011
2021 Q4	$37K	Buy	+1,412	New	+$42.6K	﹤0.01%	966
2015 Q1	–	Sell	-21,539	Closed	-$489K	–	1288
2014 Q4	$489K	Hold	21,539	–	–	﹤0.01%	1134
2014 Q3	$418K	Hold	21,539	–	–	﹤0.01%	1226
2014 Q2	$782K	Sell	21,539 -9,400	-30%	-$320K	﹤0.01%	1175
2014 Q1	$1.2M	Buy	30,939 +40	+0.1%	+$1.43K	﹤0.01%	1124
2013 Q4	$881K	Buy	30,899 +6,299	+26%	+$185K	﹤0.01%	1184
2013 Q3	$881K	Hold	24,600	–	–	﹤0.01%	1191
2013 Q2	$822K	Buy	+24,600	New	+$1.11M	﹤0.01%	1183

Other funds holding RIGL

Fidelity Investments

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $653B AUM 32.41% 1-Year Est. Return

Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Lord, Abbett & Co

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Great Point Partners Greenwich, Connecticut $408M AUM 318.81% 1-Year Est. Return

Citadel Advisors

Citadel Advisors Miami, Florida $141B AUM 30.34% 1-Year Est. Return